DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.7% ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
However, the market is expected to grow significantly between 2022 and 2032, with a projected growth rate of 7%, which is ...
ObvioHealth, a global leader in digital clinical trial solutions, announces the appointment of Richard Watkins as Chief Revenue Officer (CRO). With over 20 years of experience in sales leadership, ...
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced ...
The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...
Daily Maverick on MSN7d
Efficacy of six-monthly HIV prevention jab confirmed in second major studyIn June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback